Abstract
Safety data in chronic non-cancer pain (CNCP) with long-term opioid therapy has been poorly studied and can be differently influenced by gender. Furthermore, pharmacogenetics (PGx) could possibly be used to tailor pain medication based on the individual’s genetic background. The aim was to assess whether PGx applied to a pharmacovigilance system could help to improve a patient’s security profile. A pharmacovigilance data recording system was conducted over 24 months, including genotyping of OPRM1 variants (opioid receptor, A118G) and COMT (enzyme that degrades catecholamines such as norepinephrine, G1947A). Pain intensity (visual analogue scale, VAS), morphine equivalent daily dose (MEDD), adverse events (AEs) and suspected adverse drug reactions (ADRs) were recorded and analysed by gender. The Ethics Committee approved the study and data were analysed with R 3.6.0 software. A total of 748 patients were recruited in the study (67% female, VAS 62 ± 29 mm, MEDD 119 ± 114 mg/day) reporting a median of 6 (3.5–9) AEs/patient. Women presented more nausea, headaches, insomnia, loss of appetite, weight change, depression and dizziness than men. Analysis by genotype demonstrated that PGx influenced the prevalence of vomiting and depression in men, dizziness in women and sexual dysfunction in both. Physicians notified 150 ADRs mostly in females (79%) related to nervous system disorders. PGx applied to a pharmacovigilance recording system provides important information to achieve a better knowledge about AEs in CNCP pharmacological therapy. OPRM1 and COMT polymorphisms were associated with AEs in CNCP patients that differed according to gender.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43:983–1013.
Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–30.e122.
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama. 2016;315:1624–45.
Ricardo Buenaventura M, Rajive Adlaka M, Nalini Sehgal M. Opioid complications and side effects. Pain Physician. 2008;11:S105–S120.
Manchikanti L, Damron K, McManus C, Barnhill R. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: a prospective, observational study. Pain Physician. 2004;7:431–7.
Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. Jama. 2006;296:1858–66.
Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II. J Women’s Health Gend-based Med. 2002;11:617–29.
Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. J Women’s Health Gend-based Med. 2002;11:601–15.
Heinrich J. Most drugs withdrawn in recent years had greater health risks for women. Washington, DC: Office USGA; 2001.
Sorge RE, Mapplebeck JC, Rosen S, Beggs S, Taves S, Alexander JK, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci. 2015;18:1081–3.
Pieretti S, Di Giannuario A, Di Giovannandrea R, Marzoli F, Piccaro G, Minosi P, et al. Gender differences in pain and its relief. Ann dell’Istituto Super di Sanita. 2016;52:184–9.
Regitz-Zagrosek V. Sex and gender differences in health. Science & Society Series on Sex and Science. EMBO Rep. 2012;13:596–603.
Stannard C. Opioids and chronic pain: using what we know to change what we do. Curr Opin Supportive Palliat Care. 2016;10:129–36.
Grandhe R, Souzdalnitski D, Gritsenko K. New chronic pain treatments in the outpatient setting. Curr Pain Headache Rep. 2016;20:33.
Peiro AM, Planelles B, Juhasz G, Bagdy G, Libert F, Eschalier A, et al. Pharmacogenomics in pain treatment. Drug Metab Personalized Ther. 2016;31:131–42.
Planelles B, Margarit C, Ajo R, Sastre Y, Muriel J, Inda MM, et al. Health benefits of an adverse events reporting system for chronic pain patients using long-term opioids. Acta Anaesthesiol Scand. 2019;63:248–58.
Reed MD, Van Nostran W. Assessing pain intensity with the visual analog scale: a plea for uniformity. J Clin Pharmacol. 2014;54:241–4.
Harland NJ, Dawkin MJ, Martin D. Relative utility of a visual analogue scale vs. a six-point Likert scale in the measurement of global subject outcome in patients with low back pain receiving physiotherapy. Physiotherapy. 2015;101:50–4.
Obradovic M, Lal A, Liedgens H. Validity and responsiveness of EuroQol-5-dimension (EQ-5D) versus Short Form-6-dimension (SF-6D) questionnaire in chronic pain. Health Qual Life Outcomes. 2013;11:110.
Online information center of medicines of Spanish Agency of Medicines and Health Products (AEMPS-CIMA). 2016. https://www.apemps.gob.es.
Kelly W, Arellano F, Barnes J, Bergman U, Edwards R, Fernandez A, et al. Guidelines for submitting adverse event reports for publication. Therapie. 2009;64:289–94.
Bousquet C, Lagier G, Lillo-Le Louet A, Le Beller C, Venot A, Jaulent MC. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf. 2005;28:19–34.
Anantharaman P, Schmidt RJ. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis. 2007;14:119–25.
Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pr. 2008;8:287–313.
Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011;152:1139–45.
Muriel J, Margarit C, Planelles B, Serralta MJ, Puga C, Inda MD, et al. OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients. Ann N Y Acad Sci. 2018. https://doi.org/10.1111/nyas.13735. [Epub ahead of print].
Lotsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology. 2002;97:814–9.
De Gregori M, Garbin G, De Gregori S, Minella CE, Bugada D, Lisa A, et al. Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur J Clin Pharm. 2013;69:1651–8.
Matic M, Simons SH, van Lingen RA, van Rosmalen J, Elens L, de Wildt SN, et al. Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. Pharmacogenomics. 2014;15:1287–95.
Hu B, Zhang X, Xu G, Zhang Q, Qian P, Liu S, et al. Association between COMT polymorphism Val158Met and opioid consumption in patients with postoperative postoperative pain: a meta-analysis. Neuro-Signals. 2018;26:11–21.
Kambur O, Mannisto PT. Catechol-O-methyltransferase and pain. Int Rev Neurobiol. 2010;95:227–79.
Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5:324–36.
Zhang F, Tong J, Hu J, Zhang H, Ouyang W, Huang D, et al. COMT gene haplotypes are closely associated with postoperative fentanyl dose in patients. Anesth Analg. 2015;120:933–40.
Laugsand EA, Fladvad T, Skorpen F, Maltoni M, Kaasa S, Fayers P, et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur J Cancer. 2011;47:1682–91.
Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007;10:479–91.
Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9:1144–54.
McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–56.
Von Korff M, Deyo RA. Potent opioids for chronic musculoskeletal pain: flying blind? Pain. 2004;109:207–9.
Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother. 2007;21:15–25.
Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuijs D, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology. 2000;93:1245–54. discussion 1246A.
Dahan A, Sarton E, Teppema L, Olievier C. Sex-related differences in the influence of morphine on ventilatory control in humans. Anesthesiology. 1998;88:903–13.
Zun LS, Downey LV, Gossman W, Rosenbaumdagger J, Sussman G. Gender differences in narcotic-induced emesis in the ED. Am J Emerg Med. 2002;20:151–4.
Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Therapeutics. 2003;74:102–12.
Franconi F, Campesi I, Occhioni S, Antonini P, Murphy MF. Sex and gender in adverse drug events, addiction, and placebo. Handb Exp Pharmacol. 2012;214:107–26.
Kurita GP, Sjøgren P, Ekholm O, Kaasa S, Loge JH, Poviloniene I, et al. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol. 2011;29:1297–303.
Acknowledgements
The authors thank Mrs Esperanza Cutillas (occupational therapist specialist in pain management), Mrs Andrea Flor (pain nursery) and Raquel Ajo, Ph.D. (clinical researcher in pain management) for providing support to patients in their self-reported assessment of pain.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclosures: This work has been partially supported by the Spanish Pain Foundation (FED, grant number BF4-15-04).
Supplementary information
Rights and permissions
About this article
Cite this article
Planelles, B., Margarit, C., Inda, MdM. et al. Gender based differences, pharmacogenetics and adverse events in chronic pain management. Pharmacogenomics J 20, 320–328 (2020). https://doi.org/10.1038/s41397-019-0118-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41397-019-0118-9
This article is cited by
-
A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges
The Pharmacogenomics Journal (2022)
-
Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study
Scientific Reports (2022)
-
Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling
The Pharmacogenomics Journal (2021)
-
Risk of Fractures in Older Adults with Chronic Non-cancer Pain Receiving Concurrent Benzodiazepines and Opioids: A Nested Case–Control Study
Drugs & Aging (2021)